• Discontinuing Drug Treatment in HFrEF, Race and Sacubitril/Valsartan Use in HF, Systolic BP Polygenic Risk Score Treatment Responses

  • Oct 30 2024
  • Length: 9 mins
  • Podcast

Discontinuing Drug Treatment in HFrEF, Race and Sacubitril/Valsartan Use in HF, Systolic BP Polygenic Risk Score Treatment Responses

Listen for free

View show details

  • Summary

  • In this week’s View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart failure and reduced ejection fraction (HFrEF). He then explores the effect of race and sacubitril/valsartan use in HF patients documented in a pooled analysis of the PARADIGM-HF and PARAGON-HF trials. Finally, Dr. Eagle discusses the utility of systolic blood pressure (BP) polygenic risk scores and the treatment response in people with hypertension. Subscribe to Eagle’s Eye View
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Discontinuing Drug Treatment in HFrEF, Race and Sacubitril/Valsartan Use in HF, Systolic BP Polygenic Risk Score Treatment Responses

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available